Spyre Reports Q2 2026: $1.1B Cash, Positive Phase 2 Data, and a Wave of Catalysts

summarizeSummary

Spyre Therapeutics posted Q2 2026 results with $1.1 billion in cash and a net loss of $36.2 million. Positive Phase 2 data for SPY001 and SPY002 were highlighted, along with confirmation of multiple upcoming data readouts, including SPY003 and RA data in September.

check_boxKey Events · Earnings and Guidance · SYRE

• Strong Cash Position

  Cash, cash equivalents, and marketable securities totaled $1.1 billion as of June 30, 2026, providing expected runway into the second half of 2029.

• Positive Phase 2 Data

  SPY001 and SPY002 achieved primary endpoints in SKYLINE Part A, with clinical remission rates of 40% and 33%, respectively, and a safety profile consistent with in-class comparators.

• Upcoming Catalysts

  Six proof-of-concept readouts expected in 2026, with SPY003 Part A data and the RA sub-study of SKYWAY anticipated in September, and PsA/axSpA data in Q4.

• Financial Performance

  Q2 2026 net loss was $36.2 million, with R&D expenses of $65.5 million and G&A of $16.1 million, partially offset by a $40 million gain from a legacy asset milestone.

auto_awesomeAnalysis · SYRE · Life Sciences

A robust quarter for Spyre Therapeutics, anchored by $1.1 billion in cash that extends the runway into 2029, and positive Phase 2 induction data for SPY001 and SPY002 in ulcerative colitis. The company is poised for six proof-of-concept readouts in 2026, with the next major catalyst—SPY003 Part A data and the RA sub-study of SKYWAY—expected in September. The financial strength and clinical momentum reinforce the investment thesis, though the stock is trading near its 52-week high, suggesting much of the optimism may already be priced in.